{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:48:19Z","timestamp":1792705699692,"version":"4.5.0"},"reference-count":40,"publisher":"American Association for Cancer Research (AACR)","issue":"8","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Focal amplification and activating point mutation of the MET gene are well-characterized oncogenic drivers that confer susceptibility to targeted MET inhibitors. Recurrent somatic splice site alterations at MET exon 14 (METex14) that result in exon skipping and MET activation have been characterized, but their full diversity and prevalence across tumor types are unknown. Here, we report analysis of tumor genomic profiles from 38,028 patients to identify 221 cases with METex14 mutations (0.6%), including 126 distinct sequence variants. METex14 mutations are detected most frequently in lung adenocarcinoma (3%), but also frequently in other lung neoplasms (2.3%), brain glioma (0.4%), and tumors of unknown primary origin (0.4%). Further in vitro studies demonstrate sensitivity to MET inhibitors in cells harboring METex14 alterations. We also report three new patient cases with METex14 alterations in lung or histiocytic sarcoma tumors that showed durable response to two different MET-targeted therapies. The diversity of METex14 mutations indicates that diagnostic testing via comprehensive genomic profiling is necessary for detection in a clinical setting.<\/jats:p>\n                  <jats:p>Significance: Here we report the identification of diverse exon 14 splice site alterations in MET that result in constitutive activity of this receptor and oncogenic transformation in vitro. Patients whose tumors harbored these alterations derived meaningful clinical benefit from MET inhibitors. Collectively, these data support the role of METex14 alterations as drivers of tumorigenesis, and identify a unique subset of patients likely to derive benefit from MET inhibitors. Cancer Discov; 5(8); 850\u20139. \u00a92015 AACR.<\/jats:p>\n                  <jats:p>See related commentary by Ma, p. 802.<\/jats:p>\n                  <jats:p>See related article by Paik et al., p. 842.<\/jats:p>\n                  <jats:p>This article is highlighted in the In This Issue feature, p. 783<\/jats:p>","DOI":"10.1158\/2159-8290.cd-15-0285","type":"journal-article","created":{"date-parts":[[2015,5,13]],"date-time":"2015-05-13T21:51:34Z","timestamp":1431553894000},"page":"850-859","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":699,"title":["Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors"],"prefix":"10.1158","volume":"5","author":[{"given":"Garrett M.","family":"Frampton","sequence":"first","affiliation":[{"name":"1Foundation Medicine Inc., Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siraj M.","family":"Ali","sequence":"additional","affiliation":[{"name":"1Foundation Medicine Inc., Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Rosenzweig","sequence":"additional","affiliation":[{"name":"1Foundation Medicine Inc., Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliann","family":"Chmielecki","sequence":"additional","affiliation":[{"name":"1Foundation Medicine Inc., Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyuan","family":"Lu","sequence":"additional","affiliation":[{"name":"2Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd M.","family":"Bauer","sequence":"additional","affiliation":[{"name":"3Sarah Cannon Research Institute\/Tennessee Oncology, PLLC, Nashville, Tennessee."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail","family":"Akimov","sequence":"additional","affiliation":[{"name":"4Novartis Pharma AG, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A.","family":"Bufill","sequence":"additional","affiliation":[{"name":"5Michiana Hematology-Oncology, PC, Mishawaka, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie","family":"Lee","sequence":"additional","affiliation":[{"name":"6University of North Carolina School of Medicine, Clinical Research, Thoracic Oncology Program, Chapel Hill, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Jentz","sequence":"additional","affiliation":[{"name":"7South Bend Medical Foundation, South Bend, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rick","family":"Hoover","sequence":"additional","affiliation":[{"name":"7South Bend Medical Foundation, South Bend, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai-Hong Ignatius","family":"Ou","sequence":"additional","affiliation":[{"name":"8Division of Hematology-Oncology, Department of Medicine, University of California Irvine School of Medicine, Irvine, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Salgia","sequence":"additional","affiliation":[{"name":"9The University of Chicago School of Medicine, Chicago, Illinois."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Brennan","sequence":"additional","affiliation":[{"name":"1Foundation Medicine Inc., Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary R.","family":"Chalmers","sequence":"additional","affiliation":[{"name":"1Foundation Medicine Inc., Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savina","family":"Jaeger","sequence":"additional","affiliation":[{"name":"10Novartis Institutes for BioMedical Research, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Huang","sequence":"additional","affiliation":[{"name":"10Novartis Institutes for BioMedical Research, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia A.","family":"Elvin","sequence":"additional","affiliation":[{"name":"1Foundation Medicine Inc., Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Erlich","sequence":"additional","affiliation":[{"name":"1Foundation Medicine Inc., Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Fichtenholtz","sequence":"additional","affiliation":[{"name":"1Foundation Medicine Inc., Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle A.","family":"Gowen","sequence":"additional","affiliation":[{"name":"1Foundation Medicine Inc., Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Greenbowe","sequence":"additional","affiliation":[{"name":"1Foundation Medicine Inc., Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne","family":"Johnson","sequence":"additional","affiliation":[{"name":"1Foundation Medicine Inc., Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Depinder","family":"Khaira","sequence":"additional","affiliation":[{"name":"1Foundation Medicine Inc., Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"McMahon","sequence":"additional","affiliation":[{"name":"1Foundation Medicine Inc., Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric M.","family":"Sanford","sequence":"additional","affiliation":[{"name":"1Foundation Medicine Inc., Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Roels","sequence":"additional","affiliation":[{"name":"1Foundation Medicine Inc., Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared","family":"White","sequence":"additional","affiliation":[{"name":"1Foundation Medicine Inc., Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Greshock","sequence":"additional","affiliation":[{"name":"10Novartis Institutes for BioMedical Research, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Schlegel","sequence":"additional","affiliation":[{"name":"10Novartis Institutes for BioMedical Research, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doron","family":"Lipson","sequence":"additional","affiliation":[{"name":"1Foundation Medicine Inc., Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Yelensky","sequence":"additional","affiliation":[{"name":"1Foundation Medicine Inc., Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Morosini","sequence":"additional","affiliation":[{"name":"1Foundation Medicine Inc., Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Ross","sequence":"additional","affiliation":[{"name":"1Foundation Medicine Inc., Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Collisson","sequence":"additional","affiliation":[{"name":"2Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malte","family":"Peters","sequence":"additional","affiliation":[{"name":"4Novartis Pharma AG, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Stephens","sequence":"additional","affiliation":[{"name":"1Foundation Medicine Inc., Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent A.","family":"Miller","sequence":"additional","affiliation":[{"name":"1Foundation Medicine Inc., Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2015,8,3]]},"reference":[{"key":"2022060700114987300_bib1","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.cell.2012.01.014","article-title":"The genetic basis for cancer treatment decisions","volume":"148","author":"Dancey","year":"2012","journal-title":"Cell"},{"key":"2022060700114987300_bib2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s10555-007-9107-6","article-title":"The Met tyrosine kinase receptor in development and cancer","volume":"27","author":"Gentile","year":"2008","journal-title":"Cancer Metastasis Rev"},{"key":"2022060700114987300_bib3","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.1021\/jm401427c","article-title":"Targeting receptor tyrosine kinase MET in cancer: small molecule inhibitors and clinical progress","volume":"57","author":"Cui","year":"2014","journal-title":"J Med Chem"},{"key":"2022060700114987300_bib4","doi-asserted-by":"crossref","first-page":"6342","DOI":"10.1021\/jm2007613","article-title":"Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal\u2013epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)","volume":"54","author":"Cui","year":"2011","journal-title":"J Med Chem"},{"key":"2022060700114987300_bib5","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1097\/JTO.0b013e31821528d3","article-title":"Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification","volume":"6","author":"Ou","year":"2011","journal-title":"J Thorac Oncol"},{"key":"2022060700114987300_bib6","doi-asserted-by":"crossref","first-page":"4803","DOI":"10.1200\/JCO.2011.35.4928","article-title":"MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib","volume":"29","author":"Lennerz","year":"2011","journal-title":"J Clin Oncol"},{"key":"2022060700114987300_bib7","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1200\/JCO.2011.38.4586","article-title":"Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor","volume":"30","author":"Chi","year":"2012","journal-title":"J Clin Oncol"},{"key":"2022060700114987300_bib8","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1159\/000365326","article-title":"Durable response to crizotinib in a MET-amplified, KRAS-mutated carcinoma of unknown primary","volume":"7","author":"Palma","year":"2014","journal-title":"Case Rep Oncol"},{"key":"2022060700114987300_bib9","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1200\/JCO.2012.43.3383","article-title":"Phase II and biomarker study of the dual MET\/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma","volume":"31","author":"Choueiri","year":"2013","journal-title":"J Clin Oncol"},{"key":"2022060700114987300_bib10","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1200\/JCO.2012.47.4189","article-title":"Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer","volume":"31","author":"Spigel","year":"2013","journal-title":"J Clin Oncol"},{"key":"2022060700114987300_bib11","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1158\/2159-8290.CD-11-0175","article-title":"Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence","volume":"1","author":"Catenacci","year":"2011","journal-title":"Cancer Discov"},{"key":"2022060700114987300_bib12","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.4005","article-title":"Evaluation of MET pathway biomarkers in a phase II study of rilotumumab (R, AMG 102) or placebo (P) in combination with epirubicin, cisplatin, and capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric (G) or esophagogastric junction (EGJ) cancer","author":"Oliner","year":"2012","journal-title":"J Clin Oncol"},{"key":"2022060700114987300_bib13","first-page":"6272","article-title":"c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions","volume":"63","author":"Ma","year":"2003","journal-title":"Cancer Res"},{"key":"2022060700114987300_bib14","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1158\/0008-5472.CAN-05-2749","article-title":"Somatic mutations lead to an oncogenic deletion of met in lung cancer","volume":"66","author":"Kong-Beltran","year":"2006","journal-title":"Cancer Res"},{"key":"2022060700114987300_bib15","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1158\/0008-5472.CAN-04-2650","article-title":"Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non\u2013small cell lung cancer","volume":"65","author":"Ma","year":"2005","journal-title":"Cancer Res"},{"key":"2022060700114987300_bib16","doi-asserted-by":"crossref","first-page":"19457","DOI":"10.1016\/S0021-9258(17)32190-7","article-title":"Identification of a novel type of alternative splicing of a tyrosine kinase receptor. Juxtamembrane deletion of the c-met protein kinase C serine phosphorylation regulatory site","volume":"269","author":"Lee","year":"1994","journal-title":"J Biol Chem"},{"key":"2022060700114987300_bib17","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/emm.2006.66","article-title":"An alternatively spliced form of Met receptor is tumorigenic","volume":"38","author":"Lee","year":"2006","journal-title":"Exp Mol Med"},{"key":"2022060700114987300_bib18","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/onc.2012.551","article-title":"Cbl-independent degradation of Met: ways to avoid agonism of bivalent Met-targeting antibody","volume":"33","author":"Lee","year":"2014","journal-title":"Oncogene"},{"key":"2022060700114987300_bib19","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S1097-2765(01)00378-1","article-title":"Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein","volume":"8","author":"Peschard","year":"2001","journal-title":"Mol Cell"},{"key":"2022060700114987300_bib20","doi-asserted-by":"crossref","first-page":"9632","DOI":"10.1128\/MCB.25.21.9632-9645.2005","article-title":"Met\/Hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for Hrs phosphorylation","volume":"25","author":"Abella","year":"2005","journal-title":"Mol Cell Biol"},{"key":"2022060700114987300_bib21","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1038\/sj.onc.1202791","article-title":"Loss of the exon encoding the juxtamembrane domain is essential for the oncogenic activation of TPR-MET","volume":"18","author":"Vigna","year":"1999","journal-title":"Oncogene"},{"key":"2022060700114987300_bib22","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1111\/j.1349-7006.2008.00916.x","article-title":"Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer","volume":"99","author":"Okuda","year":"2008","journal-title":"Cancer Sci"},{"key":"2022060700114987300_bib23","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/JTO.0b013e3181913e0e","article-title":"Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers","volume":"4","author":"Onozato","year":"2009","journal-title":"J Thorac Oncol"},{"key":"2022060700114987300_bib24","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1101\/gr.145144.112","article-title":"The transcriptional landscape and mutational profile of lung adenocarcinoma","volume":"22","author":"Seo","year":"2012","journal-title":"Genome Res"},{"key":"2022060700114987300_bib25","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","author":"Cancer Genome Atlas Research Network","year":"2014","journal-title":"Nature"},{"key":"2022060700114987300_bib26","doi-asserted-by":"crossref","first-page":"5893","DOI":"10.1038\/ncomms6893","article-title":"Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes","volume":"5","author":"Dhanasekaran","year":"2014","journal-title":"Nat Commun"},{"key":"2022060700114987300_bib27","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1136\/jclinpath-2012-201375","article-title":"Identification of MET genomic amplification, protein expression and alternative splice isoforms in neuroblastomas","volume":"66","author":"Yan","year":"2013","journal-title":"J Clin Pathol"},{"key":"2022060700114987300_bib28","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.bbrc.2010.03.120","article-title":"Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletion","volume":"394","author":"Asaoka","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"2022060700114987300_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.cllc.2015.01.009","article-title":"Response to crizotinib in a patient with lung adenocarcinoma harboring a MET splice site mutation","author":"Jenkins","year":"2015  7","journal-title":"Clin Lung Cancer"},{"key":"2022060700114987300_bib30","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1097\/JTO.0000000000000478","article-title":"MET mutation associated with responsiveness to crizotinib","volume":"10","author":"Waqar","year":"2015","journal-title":"J Thorac Oncol"},{"key":"2022060700114987300_bib31","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1097\/JTO.0000000000000491","article-title":"MET-mutated NSCLC with major response to crizotinib","volume":"10","author":"Mendenhall","year":"2015","journal-title":"J Thorac Oncol"},{"key":"2022060700114987300_bib32","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing","volume":"31","author":"Frampton","year":"2013","journal-title":"Nat Biotechnol"},{"key":"2022060700114987300_bib33","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nm.2697","article-title":"Chipping away at the lung cancer genome","volume":"18","author":"Pao","year":"2012","journal-title":"Nat Med"},{"key":"2022060700114987300_bib34","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.cell.2012.08.029","article-title":"Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing","volume":"150","author":"Imielinski","year":"2012","journal-title":"Cell"},{"key":"2022060700114987300_bib35","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/sj.bjc.6604886","article-title":"LKB1\/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signaling inhibition","volume":"100","author":"Mahoney","year":"2009","journal-title":"Br J Cancer"},{"key":"2022060700114987300_bib36","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1097\/JTO.0000000000000173","article-title":"LKB1 Loss induces characteristic patterns of gene expression in human tumors associated with NRF2 activation and attenuation of PI3K-AKT","volume":"9","author":"Kaufman","year":"2014","journal-title":"J Thorac Oncol"},{"key":"2022060700114987300_bib37","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nature07423","article-title":"Somatic mutations affect key pathways in lung adenocarcinoma","volume":"455","author":"Ding","year":"2008","journal-title":"Nature"},{"key":"2022060700114987300_bib38","doi-asserted-by":"crossref","first-page":"7127","DOI":"10.1158\/1078-0432.CCR-11-1157","article-title":"A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3","volume":"17","author":"Liu","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2022060700114987300_bib39","doi-asserted-by":"crossref","first-page":"5s","DOI":"10.1200\/jco.2014.32.15_suppl.2520","article-title":"Phase I study of the safety and efficacy of INC280 in patients with advanced MET-dependent solid tumors","volume":"32","author":"Bang","year":"2014","journal-title":"J Clin Oncol"},{"key":"2022060700114987300_bib40","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1083\/jcb.200309102","article-title":"Autocrine CSF-1R activation promotes Src-dependent disruption of mammary epithelial architecture","volume":"165","author":"Wrobel","year":"2004","journal-title":"J Cell Biol"}],"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/5\/8\/850\/1823056\/850.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/5\/8\/850\/1823056\/850.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T20:12:42Z","timestamp":1654546362000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/5\/8\/850\/5045\/Activation-of-MET-via-Diverse-Exon-14-Splicing"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,1]]},"references-count":40,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2015,8,3]]},"published-print":{"date-parts":[[2015,8,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-15-0285","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2159-8290.22530219","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22530225.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22530222.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22530216","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.c.6546132.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22530225","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22530222","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.c.6546132","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22530219.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22530216.v1","asserted-by":"object"}]},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,1]]}}}